These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 21455987

  • 1. Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas.
    Kogias E, Osterberg N, Baumer B, Psarras N, Koentges C, Papazoglou A, Saavedra JE, Keefer LK, Weyerbrock A.
    Int J Cancer; 2012 Mar 01; 130(5):1184-94. PubMed ID: 21455987
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug.
    Findlay VJ, Townsend DM, Saavedra JE, Buzard GS, Citro ML, Keefer LK, Ji X, Tew KD.
    Mol Pharmacol; 2004 May 01; 65(5):1070-9. PubMed ID: 15102935
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
    Grossman R, Brastianos H, Blakeley JO, Mangraviti A, Lal B, Zadnik P, Hwang L, Wicks RT, Goodwin RC, Brem H, Tyler B.
    J Neurooncol; 2014 Jan 01; 116(1):59-65. PubMed ID: 24185441
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The nitric oxide donor JS-K sensitizes U87 glioma cells to repetitive irradiation.
    Heckler M, Osterberg N, Guenzle J, Thiede-Stan NK, Reichardt W, Weidensteiner C, Saavedra JE, Weyerbrock A.
    Tumour Biol; 2017 Jun 01; 39(6):1010428317703922. PubMed ID: 28653883
    [Abstract] [Full Text] [Related]

  • 10. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
    Grossman R, Tyler B, Rudek MA, Kim E, Zadnik P, Khan U, Blakeley JO, Pathak AP, Brem H.
    Cancer Chemother Pharmacol; 2013 Jul 01; 72(1):93-100. PubMed ID: 23649683
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Growth inhibition and chemosensitization of exogenous nitric oxide released from NONOates in glioma cells in vitro.
    Weyerbrock A, Baumer B, Papazoglou A.
    J Neurosurg; 2009 Jan 01; 110(1):128-36. PubMed ID: 18991497
    [Abstract] [Full Text] [Related]

  • 13. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
    Dong J, Zhou G, Tang D, Chen Y, Cui B, Dai X, Zhang J, Lan Q, Huang Q.
    J Cancer Res Clin Oncol; 2012 Dec 01; 138(12):2079-84. PubMed ID: 22825126
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.
    Li XQ, Ouyang ZG, Zhang SH, Liu H, Shang Y, Li Y, Zhen YS.
    J Neurooncol; 2014 Aug 01; 119(1):91-100. PubMed ID: 24842385
    [Abstract] [Full Text] [Related]

  • 16. Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: Structural analogues of PABA/NO, an anti-cancer lead compound.
    Chakrapani H, Wilde TC, Citro ML, Goodblatt MM, Keefer LK, Saavedra JE.
    Bioorg Med Chem; 2008 Mar 01; 16(5):2657-64. PubMed ID: 18060792
    [Abstract] [Full Text] [Related]

  • 17. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
    D'Alessandro G, Grimaldi A, Chece G, Porzia A, Esposito V, Santoro A, Salvati M, Mainiero F, Ragozzino D, Di Angelantonio S, Wulff H, Catalano M, Limatola C.
    Oncotarget; 2016 May 24; 7(21):30781-96. PubMed ID: 27096953
    [Abstract] [Full Text] [Related]

  • 18. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
    Saito R, Bringas JR, Panner A, Tamas M, Pieper RO, Berger MS, Bankiewicz KS.
    Cancer Res; 2004 Oct 01; 64(19):6858-62. PubMed ID: 15466173
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.